No matches
Pulmonology

How FeNO Measurement Can Improve Severe Asthma Management — Presented in Spanish by Dr. Miguel Lanz

Join Dr. Miguel Lanz as he explains, in Spanish, the clinical utility of FeNO as a biomarker in severe asthma.
Miguel Lanz
MD, FAAAAI
Miguel Lanz

Related resources

Type 2 Inflammation Underpins Pediatric Severe Asthma

Type 2 Inflammation Underpins Pediatric Severe Asthma

Infographic
ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Podcast
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Podcast
Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
ERS 2024 | Understanding the Complex Pathophysiology of COPD

ERS 2024 | Understanding the Complex Pathophysiology of COPD

expert video
COPD and Asthma: What's the Difference and Is There a Link?

COPD and Asthma: What's the Difference and Is There a Link?

interactivity
What Are the Key Inflammatory Processes in Patients with COPD?

What Are the Key Inflammatory Processes in Patients with COPD?

expert video
FeNO as a Biomarker for Type 2 Asthma

FeNO as a Biomarker for Type 2 Asthma

expert video
IgE as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

expert video
Pediatric Asthma Patient Case Tool: Ash

Pediatric Asthma Patient Case Tool: Ash

interactivity
The Cycle of Inflammation in Adult Asthma

The Cycle of Inflammation in Adult Asthma

interactivity
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Infographic
Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

expert video
ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

expert video
ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

Podcast
Blood Eosinophils: A Biomarker in COPD

Blood Eosinophils: A Biomarker in COPD

Infographic
GOLD 2023 | Clinical Presentation of COPD and Disease Burden

GOLD 2023 | Clinical Presentation of COPD and Disease Burden

expert video
What Do We Know About Type 2 Inflammation in COPD?

What Do We Know About Type 2 Inflammation in COPD?

expert video
What Differentiates COPD Exacerbations From Asthma Exacerbations?

What Differentiates COPD Exacerbations From Asthma Exacerbations?

expert video
Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

videoanimation
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

expert video
ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

expert video
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

expert video
What Is The COPD Vicious Cycle?

What Is The COPD Vicious Cycle?

expert video
Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

videoanimation
Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

interactivity
Adult Asthma Interactive Patient Cases

Adult Asthma Interactive Patient Cases

interactivity
ADVENT On Air | Pulmonary Perspectives: Understanding COPD Patient Burden

ADVENT On Air | Pulmonary Perspectives: Understanding COPD Patient Burden

Podcast
ADVENT On Air | Role of Type 2 Inflammation in COPD

ADVENT On Air | Role of Type 2 Inflammation in COPD

Podcast
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

expert video
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

expert video
ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes

ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes

Podcast
ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

expert video
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

expert video
ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

expert video
Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

expert video
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
How Can FeNO Measurement Improve Severe Asthma Management?

How Can FeNO Measurement Improve Severe Asthma Management?

expert video
GOLD Diagnosis and Assessment of COPD

GOLD Diagnosis and Assessment of COPD

expert video
Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

interactivity
Eosinophils: A Biomarker in COPD

Eosinophils: A Biomarker in COPD

Infographic
Uncovering the Impact of Moderate COPD Exacerbations

Uncovering the Impact of Moderate COPD Exacerbations

interactivity
Lung Function Decline: Why it Matters and What’s at Stake for Patients

Lung Function Decline: Why it Matters and What’s at Stake for Patients

interactivity
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

expert video
Mucus Plugging as a Potential Target in Asthma Management

Mucus Plugging as a Potential Target in Asthma Management

expert video
Multifaceted Role of IL-13 in Airway Remodeling

Multifaceted Role of IL-13 in Airway Remodeling

expert video
Pediatric Asthma Trajectory and Clinical Remission

Pediatric Asthma Trajectory and Clinical Remission

expert video

Learning objectives

  • Identify how type 2 inflammation leads to an increase in exhaled nitric oxide in severe asthma patients
  • Understand the clinical utility of FeNO as a diagnostic, prognostic, and predictive biomarker of severe asthma
Tags
fenoacross eoe
MAT-GLB-2507044 - 1.0 - 12/2025

About this expert

Allergy/Immunology
Pulmonology

Miguel Lanz

MD, FAAAAI

Lanz Allergy, Asthma & Immunology AAADRS Clinical Research Center | Coral Gables, FL

See author’s profile
Miguel Lanz

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region